InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Form 604 - Change in Substantial Shareholding (Authentics) 5 May 2017 8:59AM $0.560 $0.046 fallen by 91.79%
$15 Form 603 - Initial Substantial Shareholder (Authentics) 5 May 2017 8:58AM $0.560 $0.046 fallen by 91.79%
$15 Positive Results of IMM-124E in Acute Colitis Studies 18 Apr 2017 10:34AM $0.425 $0.046 fallen by 89.18%
$15 Immuron Update on US Listing - Proceeding as Planned 11 Apr 2017 11:49AM $0.410 $0.046 fallen by 88.78%
$15 Immuron Update on Listing - Process Proceeding as Planned 11 Apr 2017 9:56AM $0.430 $0.046 fallen by 89.30%
$15 Immuron Files Amended Form F-1 with the SEC 10 Apr 2017 4:56PM $0.400 $0.046 fallen by 88.50%
$15 Director Appointment - Prof. Ravi Savarirayan 7 Apr 2017 10:34AM $0.395 $0.046 fallen by 88.35%
$15 Close of Recruitment of Phase II NASH Trial 6 Apr 2017 12:47AM $0.395 $0.046 fallen by 88.35%
$15 Appendix 4D - Half Year Report and Accounts - Dec 2016 28 Feb 2017 6:04PM $0.295 $0.046 fallen by 84.41%
$15 Immuron Completes Phase II NASH Clinical Trial Recruitment 20 Feb 2017 11:44AM $0.310 $0.046 fallen by 85.16%
$15 Immuron Files Amended Form F-1 with the SEC 9 Feb 2017 1:48PM $0.300 $0.046 fallen by 84.67%
$15 First Patient in Pediatric Fatty-Liver Phase II Trial 6 Feb 2017 12:22AM $0.300 $0.046 fallen by 84.67%
$15 NASH MOA Study commences with SanyalBio & Duke University 19 Jan 2017 11:09AM $0.295 $0.046 fallen by 84.41%
$15 European/US Analyst - Immuron Moving to Forefront in NASH 18 Jan 2017 9:45AM $0.265 $0.046 fallen by 82.64%
$15 Gilead Pays $100M NASH Related Milestone to Phenex 9 Jan 2017 12:11AM $0.280 $0.046 fallen by 83.57%
$15 JNJ, BMS and Novartis Complete NASH Asset Transactions 6 Jan 2017 12:01AM $0.280 $0.046 fallen by 83.57%
$15 Immuron Files Form F-1 with the SEC 22 Dec 2016 10:15AM $0.280 $0.046 fallen by 83.57%
$15 Appendix 3B - Issue of Options Under ESOP 9 Dec 2016 1:02PM $0.295 $0.046 fallen by 84.41%
$15 Form 604 - Change in Substantial Shareholding (Grandlodge) 7 Dec 2016 6:29PM $0.290 $0.046 fallen by 84.14%
$15 Appendix 3Y - Change of Director's Interest Notices (x4) 2 Dec 2016 5:19PM $0.320 $0.046 fallen by 85.63%
$15 Appendix 3B - Issue of Rights Issue Options & ESOP Shares 2 Dec 2016 5:15PM $0.320 $0.046 fallen by 85.63%
$15 Results of 2016 Annual General Meeting 29 Nov 2016 2:40PM $0.335 $0.046 fallen by 86.27%
$15 2016 AGM Presentation 29 Nov 2016 11:04AM $0.300 $0.046 fallen by 84.67%
$15 Immuron Receives $1.6M R&D Tax Concession Refund 29 Nov 2016 10:29AM $0.300 $0.046 fallen by 84.67%
$15 Notice of 2016 Annual General Meeting 28 Oct 2016 6:36PM $0.300 $0.046 fallen by 84.67%

576 - 600 of 782 results

Page 24 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.